Skip to content
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases

Press Releases

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

April 8, 2024
Read More »

Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)

March 25, 2024
Read More »

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina

November 12, 2023
Read More »

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy

November 7, 2023
Read More »

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

August 16, 2023
Read More »

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy

June 5, 2023
Read More »
Page1 Page2 Page3 Page4 Page5
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
CONTACT

Privacy Policy      Terms of Use

2025 © Imbria Pharmaceuticals​

Linkedin